Chunhong Hu

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hung-Ming Wang, Ruifeng Xu, Jianji Pan, 2021, Nature Medicine.

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

Li Zhang, P. Cao, S. Zeng, 2021, Frontiers in Oncology.

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

J Zhang, Jianxing He, Guangfa Wang, 2021, Cancer communications.

NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma

Yan Tang, Chunhong Hu, 2021, Disease markers.

JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

Hung-Ming Wang, Ji-Rong Wen, Jianji Pan, 2021 .